Journal article
The Thrombospondin-1 Mimetic ABT-510 Increases the Uptake and Effectiveness of Cisplatin and Paclitaxel in a Mouse Model of Epithelial Ovarian Cancer
Abstract
Epithelial ovarian cancer (EOC) comprises approximately 90% of ovarian cancers and arises from the surface epithelium. Typical treatment of EOC involves cytoreductive surgery combined with chemotherapy. More recent therapies have targeted the tumor vasculature using antiangiogenic compounds such as thrombospondin-1 (TSP-1). TSP-1 mimetic peptides such as ABT-510 have been created and have been in various clinical trials. We have previously …
Authors
Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
Journal
Neoplasia, Vol. 12, No. 3, pp. 275–283
Publisher
Elsevier
Publication Date
3 2010
DOI
10.1593/neo.91880
ISSN
1522-8002
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomimeticsCell LineCisplatinEndothelium, VascularEnzyme-Linked Immunosorbent AssayFemaleImmunoblottingMiceMice, Inbred C57BLMorbidityNeoplasms, Glandular and EpithelialOligopeptidesOvarian NeoplasmsPaclitaxelReceptors, Vascular Endothelial Growth FactorSurvival RateThrombospondin 1Treatment OutcomeVascular Endothelial Growth Factor AXenograft Model Antitumor Assays